Kakeru Hisakane
YOU?
Author Swipe
View article: Palliative surgery is effective in patients with EGFR-mutant lung adenocarcinoma with pleural metastasis
Palliative surgery is effective in patients with EGFR-mutant lung adenocarcinoma with pleural metastasis Open
Compared with EGFR-TKI monotherapy, palliative surgery combined with EGFR-TKI treatment prolonged the PFS of pleural metastatic EGFR-LUADm patients. A subset of EGFR-LUADm patients with pleural metastasis might …
View article: Allergic bronchopulmonary mycosis induced by pembrolizumab for bladder cancer: A case report
Allergic bronchopulmonary mycosis induced by pembrolizumab for bladder cancer: A case report Open
Pembrolizumab is an immune checkpoint inhibitor (ICI) of programmed cell death-1 category, used for treating various types of cancer. ICIs can sometimes result in immune-related adverse events. Allergic bronchopulmonary mycosis (ABPM) indu…
View article: Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of<i>ABCB1</i>in Non-small Cell Lung Cancer
Ivermectin Enhances Paclitaxel Efficacy by Overcoming Resistance Through Modulation of<i>ABCB1</i>in Non-small Cell Lung Cancer Open
Combined treatment of PTX-resistant A549 cells with ivermectin and PTX may circumvent PTX resistance caused by P-gp induction, highlighting a novel therapeutic avenue for drug repurposing.
View article: Correlations between 14-gene RNA-level assay and clinical and molecular features in resectable non-squamous non-small cell lung cancer: a cross-sectional study
Correlations between 14-gene RNA-level assay and clinical and molecular features in resectable non-squamous non-small cell lung cancer: a cross-sectional study Open
Our results indicate that 14-gene RNA-level assay is correlated with specific genetic mutations, including TP53, KRAS, and LRP1B. These insights provide a stronger foundation for integrating molecular risk assessment w…
View article: Histopathologic pattern and molecular risk stratification are associated with prognosis in patients with stage IB lung adenocarcinoma
Histopathologic pattern and molecular risk stratification are associated with prognosis in patients with stage IB lung adenocarcinoma Open
Our study showed that both the MIP/SOL pattern and molecular high-risk category were adverse prognostic factors in stage IB NSCLC patients. Our results suggest that combining histologic classification and molecular risk stratification may …
View article: Utility of atezolizumab plus bevacizumab, carboplatin, and paclitaxel combination for the treatment of advanced non-squamous non-small cell lung cancer patients with malignant pleural effusion
Utility of atezolizumab plus bevacizumab, carboplatin, and paclitaxel combination for the treatment of advanced non-squamous non-small cell lung cancer patients with malignant pleural effusion Open
The ABCP regimen may be a promising treatment option for non-squamous NSCLC patients with MPE.
View article: Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series
Safety and Efficacy of Gefitinib Administration After Osimertinib-Induced Interstitial Lung Disease: A Six-Case Series Open
The treatment with gefitinib after the development of osi-ILD was safe and effective. Gefitinib may be a promising option for patients who recovered from severe osi-ILD.
View article: Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer
Immunotherapy or Chemoimmunotherapy in Older Adults With Advanced Non–Small Cell Lung Cancer Open
Importance Immune checkpoint inhibitor (ICI) plus chemotherapy combination treatment (ICI-chemotherapy) is now a standard treatment for non–small cell lung cancer (NSCLC) without targetable oncogene alterations, but there are few data on I…
View article: Evaluation of sarcoidosis with multiple bone lesions using both bone scintigraphy and FDG-PET/CT: A case report
Evaluation of sarcoidosis with multiple bone lesions using both bone scintigraphy and FDG-PET/CT: A case report Open
Sarcoidosis is a systemic granulomatous disease; however, the incidence of bone sarcoidosis is relatively rare. The short tubular bones of the hands and feet are most frequently affected, while the vertebrae and the pelvic bones are rarely…
View article: 1350P Survival benefits of local treatment (LT) for brain metastases (BMs) in patients (pts) with EGFR-mutant non-small cell lung cancer (EGFR-mt NSCLC) treated with osimertinib
1350P Survival benefits of local treatment (LT) for brain metastases (BMs) in patients (pts) with EGFR-mutant non-small cell lung cancer (EGFR-mt NSCLC) treated with osimertinib Open
View article: Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer
Thyroid transcription factor-1 (TTF-1) expression and the efficacy of combination therapy with immune checkpoint inhibitors and cytotoxic chemotherapy in non-squamous non-small cell lung cancer Open
ICI monotherapy is generally less efficacious in TTF-1-negative NS-NSCLC patients, and clinicians should consider ICI plus chemotherapy in these cases. Our study suggests that ABCP is an optimal regimen for TTF-1-negative NS-NSCLC.
View article: A remarkable response to combination chemotherapy with nivolumab and ipilimumab in a patient with primary pulmonary choriocarcinoma: a case report
A remarkable response to combination chemotherapy with nivolumab and ipilimumab in a patient with primary pulmonary choriocarcinoma: a case report Open
This is the first case of postoperative relapse PPC that has been successfully treated with the combination of chemotherapy, nivolumab, and ipilimumab. This therapy may be a promising option for advanced PPC.
View article: Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study
Platinum‐combination chemotherapy with or without immune‐checkpoint inhibitor in patients with postoperative recurrent non‐small cell lung cancer previously treated with adjuvant platinum‐doublet chemotherapy: A multicenter retrospective study Open
Background Rechallenge with platinum‐combination chemotherapy in patients with advanced non‐small cell lung cancer (NSCLC) after disease progression on platinum‐combination chemotherapy occasionally leads to a favorable response. The effic…
View article: Development of eosinophilic pneumonia from eosinophilic bronchiolitis without asthma: A case report
Development of eosinophilic pneumonia from eosinophilic bronchiolitis without asthma: A case report Open
Eosinophilic bronchiolitis is a disease concept reported in Japan in 2001, that presents with bronchiolitis accompanied by eosinophilia in the blood and lungs. In 2013, hypereosinophilic obliterative bronchiolitis, as a group of disease pr…
View article: A Case of Pseudo-progression-like Pleurisy After Combined Treatment with Nivolumab and Ipilimumab for Lung Adenocarcinoma
A Case of Pseudo-progression-like Pleurisy After Combined Treatment with Nivolumab and Ipilimumab for Lung Adenocarcinoma Open
背景.免疫チェックポイント阻害薬によるpseudo-progressionは非小細胞肺癌患者の約5%にみられるが,免疫チェックポイント阻害薬単剤における報告がほとんどである.今回,ニボルマブ+イピリムマブ併用療法後に胸膜炎様のpseudo-progressionを認めた肺腺癌の1例を経験した.症例.70歳,男性.胸膜播種を伴う肺腺癌pT3N0M1a stage IVAに対し1次治療としてカルボプラチン+ペメトレキセド+ニボルマブ+イピリムマブを投与した.投与後から発熱,呼吸…
View article: Black pleural effusion caused by a pancreaticopleural fistula associated with autoimmune pancreatitis: A case report
Black pleural effusion caused by a pancreaticopleural fistula associated with autoimmune pancreatitis: A case report Open
Rationale: Black pleural effusion is a rare medical condition and a diagnostic marker. Pancreaticopleural fistula is one of the causes of black pleural effusion. Thus far, black pleural effusions caused by pancreaticopleural fistulae have …
View article: A Case of Fulminant Type 1 Diabetes Mellitus After the Administration of Durvalumab for Small-cell Lung Cancer
A Case of Fulminant Type 1 Diabetes Mellitus After the Administration of Durvalumab for Small-cell Lung Cancer Open
背景.免疫チェックポイント阻害薬による劇症1型糖尿病は稀な有害事象である.肺癌においては非小細胞肺癌での報告が散見される.今回,小細胞肺癌に対するデュルバルマブ投与後に劇症1型糖尿病を発症した症例を経験した.症例.71歳男性,Performance Status 1.糖尿病の既往歴なし.進展型小細胞肺癌cT4N3M1b stage IVAに対して,20XX年5月よりカルボプラチン+エトポシド+デュルバルマブ併用療法が開始された.Day 27より食欲不振,倦怠感が出現し,2コ…
View article: Active pulmonary interstitial fibrosis in a COVID-19 survivor diagnosed by transbronchial lung cryobiopsy six months after onset
Active pulmonary interstitial fibrosis in a COVID-19 survivor diagnosed by transbronchial lung cryobiopsy six months after onset Open
View article: Carboplatin plus nanoparticle albumin‑bound paclitaxel for the treatment of thymic carcinoma
Carboplatin plus nanoparticle albumin‑bound paclitaxel for the treatment of thymic carcinoma Open
Thymic carcinoma is a relatively rare type of malignant tumor. The present retrospective study evaluated the efficacy and safety of carboplatin plus nanoparticle albumin-bound paclitaxel for the treatment of advanced thymic carcinoma. The …
View article: A Novel Molecular Target in <i>EGFR</i>-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed
A Novel Molecular Target in <i>EGFR</i>-mutant Lung Cancer Treated With the Combination of Osimertinib and Pemetrexed Open
Blocking PLK1 contributes to mediating the synergistic anti-proliferative effect of osimertinib+pemetrexed. PLK1 over-expression may be a critical mechanism for acquired resistance to osimertinib+pemetrexed.
View article: P15‐7: Bosentan has potential benefits in patients with exercise OR mild‐to‐moderate pulmonary hypertension associated with COPD
P15‐7: Bosentan has potential benefits in patients with exercise OR mild‐to‐moderate pulmonary hypertension associated with COPD Open
View article: Exosome‐derived <scp>miR</scp>‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in <scp><i>EGFR</i></scp> mutant non‐small cell lung cancer cells
Exosome‐derived <span>miR</span>‐210 involved in resistance to osimertinib and epithelial–mesenchymal transition in <span><i>EGFR</i></span> mutant non‐small cell lung cancer cells Open
Background Osimertinib is a third‐generation epidermal growth factor receptor‐tyrosine kinase inhibitor (EGFR‐TKI) approved for the treatment of patients with EGFR ‐mutant non‐small cell lung cancer (NSCLC). However, the mechanisms of acqu…
View article: A Novel Molecular Target in EGFR-Mutant Non-Small Cell Lung Cancer Treated With a Combination of Osimertinib and Pemetrexed
A Novel Molecular Target in EGFR-Mutant Non-Small Cell Lung Cancer Treated With a Combination of Osimertinib and Pemetrexed Open
Overcoming acquired resistance to the epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI) osimertinib is currently an important clinical issue in treating EGFR-mutant non-small cell lung cancer (NSCLC) patients. EGFR-TKI …
View article: Feasibility and utility of transbronchial cryobiopsy in precision medicine for lung cancer: Prospective single‐arm study
Feasibility and utility of transbronchial cryobiopsy in precision medicine for lung cancer: Prospective single‐arm study Open
Cryoprobe is a novel transbronchial biopsy (TBB) tool that yields larger tissue samples than forceps. Pathological diagnosis and biomarker analysis, such as genetic alterations and programmed death‐ligand 1 (PD‐L1) expression, are paramoun…
View article: Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer
Immune checkpoint inhibitor‐associated interstitial lung diseases correlate with better prognosis in patients with advanced non‐small‐cell lung cancer Open
Background Interstitial lung disease (ILD) induced by immune checkpoint inhibitors (ICIs) is a potentially life‐threatening adverse event. The purpose of this study was to evaluate whether the development of immune‐related adverse events (…
View article: Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small cell lung cancer patients
Interstitial lung disease induced by immune-checkpoint inhibitors correlates with prognosis of advanced non-small cell lung cancer patients Open
View article: Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis
Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis Open
An 82-year-old man with a recurrence of pulmonary pleomorphic carcinoma was treated with pembrolizumab. He achieved partial response after three cycles of pembrolizumab. However, he developed febrile neutropenia. A bone marrow aspiration s…
View article: Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression
Pembrolizumab and salvage chemotherapy in EGFR T790M-positive non-small-cell lung cancer with high PD-L1 expression Open
Immuno-checkpoint inhibitors (ICI) have become an effective treatment option for non-small-cell lung cancer patients. However, ICI therapy was reported to be less effective in patients with epidermal growth factor receptor (EGFR) mutations…
View article: Long-term survival after complete resection of non-small-cell lung cancer in patients with interstitial lung disease
Long-term survival after complete resection of non-small-cell lung cancer in patients with interstitial lung disease Open
The presence of ILD led to a much poorer survival after complete resection of non-small-cell lung cancer.
View article: Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer
Salvage chemoradiotherapy with cisplatin and vinorelbine for postoperative locoregional recurrence of non-small cell lung cancer Open
Although a few investigators have demonstrated the effect of concurrent chemoradiotherapy (CRT) for postoperative recurrent non-small cell lung cancer (NSCLC), the outcome of this treatment remains unclear. The aim of this study was to elu…